Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05105679 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Experimental intervention: PF-05105679 or placebo | EXPERIMENTAL | Cohort 1 |
| Cohort 2: Experimental intervention: PF-05105679 or placebo | EXPERIMENTAL | Cohort 2 |
| Cohort 3: Experimental intervention PF-05105679 or placebo and | ACTIVE_COMPARATOR | Cohort 3 |
| Name | Type | Description |
|---|---|---|
| PF-05105679 | DRUG | Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679 |
Inclusion Criteria: Healthy Volunteers Exclusion Criteria: Standard Healthy Volunteers
PF-05105679 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial involving healthy adult male volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early-stage clinical development.
PF-05105679 is made and developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 clinical trial of the compound. No partnership or licensing arrangement for PF-05105679 has been disclosed.
PF-05105679 is in Phase 1 clinical development. Its only recorded trial, NCT01393652, was a Phase 1 study that has been completed. The compound is investigational and has not been approved by the FDA for any indication.
PF-05105679 has been evaluated in one clinical trial, NCT01393652, titled Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679. The Phase 1 trial enrolled 32 healthy male volunteers in Belgium, was randomized, double-blind, and active-controlled, and is now completed. No active trials are ongoing.
No. PF-05105679 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. Its single completed trial, NCT01393652, studied the compound in healthy volunteers rather than in patients with a specific disease.
The Phase 1 trial NCT01393652 studied single-dose escalation of PF-05105679 in healthy volunteers. It enrolled 32 male participants aged 18 years and older in Belgium. The study was randomized, double-blind, and active-controlled, and it has been completed.